Recombinant LH(San Carlo Public Hospital, Potenza, Italy)(Recombinant LH(San Carlo Public Hospital, Potenza, Italy))

概要

基本信息

药物类型

激素

别名

Luveris rLH by Merck Serono

靶点-

作用机制-

治疗领域

内分泌与代谢疾病泌尿生殖系统疾病其他疾病

在研适应症-

非在研适应症

卵巢过度刺激综合征

原研机构-

在研机构-

非在研机构-

最高研发阶段无进展临床阶段不明

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

5

项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的临床试验

ChiCTR2000031843 / Recruiting临床4期IIT

Dosage of recombinant LH supplementation in women with previous unexpected hypo-response to conventional ovarian stimulation: a prospective, randomized, controlled, assessor-blind study

开始日期2020-04-01

申办/合作机构

Sun Yat-Sen Memorial Hospital

NCT02200952 / CompletedN/AIIT

Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS

The purpose of this study is to prove that luteal phase supplementation with recombinant LH can solve the luteal phase deficiency after Gnrh agonist oocytes triggering in women at risk of OHSS

开始日期2013-06-30

申办/合作机构-

EUCTR2010-022032-37-IT / Not yet recruitingN/A

Randomized, open-label, single centre study on ovarian stimulation in ART poor responders treated with recombinant FSH in association with recombinant LH.

开始日期2011-03-18

申办/合作机构

Casa di Cura Abano Terme Polispecialistica e Termale SpA

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的专利（医药）

登录后查看更多信息

128

项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的文献（医药）

2024-11-01·Experimental Eye Research

FK962 protects retinal ganglion cell under hypoxia/reoxygenation: Possible involvement of glial cell line-derived neurotrophic factor signaling pathway

Article

作者: Kishimoto, Yayoi ; Kobayashi-Otsugu, Momoko ; Fukiage, Chiho ; Azuma, Mitsuyoshi

Loss of retinal ganglion cells (RGCs) is the cause of visual impairment and blindness in glaucoma. Previously, our studies showed that FK962 (N-[1-acetylpiperidin-4-yl]-4-fluorobenzamide) promoted neurite elongation in rat RGCs and trigeminal ganglion (TG) cells. In TG cells, glial cell line-derived neurotrophic factor (GDNF) is known to be involved in the mechanism. The purpose of the present study is to investigate whether, 1) FK962 shows an RGC-protective effect under hypoxia/reoxygenation (H/R) and 2) GDNF is involved in the neuroprotective mechanism of FK962. Rat primary retinal cells were cultured under 24-h hypoxia/24-h reoxygenation conditions, with or without FK962, recombinant GDNF, GDNF antibody and RET receptor tyrosine kinase inhibitor, GSK3179106. Cells were co-immunostained with RBPMS and Neurofilament 200 as a RGC marker, and the number of survived RGCs was counted. Results showed H/R treatment decreased the number of survived RGCs. FK962 promoted RGC survival under H/R by a bell-shaped dose response, with the highest RGC-protective effect of 10^-8 M. The protective effect was the same level with 10^-12 M exogenous GDNF. Addition of GDNF antibody or GSK3179106 counteracted the neuroprotective effect of FK962. From these results, it is suggested that FK962 ameliorates RGC death under H/R, possibly via a GDNF signaling pathway.

2024-10-01·Human Reproduction

Undetected, natural conception pregnancies in luteal phase stimulations—case series and review of literature

Article

作者: Del Gallego, R ; Edades, J ; Kalafat, E ; Fatemi, H ; Ata, B ; Selim, S ; Lawrenz, B

AbstractSTUDY QUESTIONWhat is the risk of an undetected natural conception pregnancy during luteal phase ovarian stimulation, and how does it impact the pregnancy's course?SUMMARY ANSWERThe risk for an undetected, natural conception pregnancy in luteal phase ovarian stimulation is low and it appears that ovarian stimulation is unlikely to harm the pregnancy.WHAT IS KNOWN ALREADYRandom start ovarian stimulation appears to be similarly effective as early follicular stimulation start; and it allows ovarian stimulation to be started independent of the cycle day and throughout the cycle, in accordance with the patients’ and clinics’ schedule as long as there is no intention of a fresh embryo transfer in the same cycle. Starting ovarian stimulation in the luteal phase bears the possibility of an—at the timepoint of stimulation start—undetected, natural conception pregnancy that has already occurred. There is scarce data on the incidence of this event as well as on the possible implications of ovarian stimulation on the course of an existing pregnancy.STUDY DESIGN, SIZE, DURATIONThis retrospective observational study, performed between June 2017 and January 2024, analyzed luteal phase stimulations, in which a natural conception pregnancy was detected during the ovarian stimulation treatment for IVF/ICSI. Luteal phase stimulation was defined as ovarian stimulation started after ovulation and before the next expected menstrual bleeding, with a serum progesterone (P4) level of >1.5 ng/ml on the day of stimulation start or 1 day before.PARTICIPANTS/MATERIALS, SETTING, METHODSWomen who underwent a luteal phase ovarian stimulation in a tertiary referral ART center.MAIN RESULTS AND THE ROLE OF CHANCEA total of 488 luteal phase stimulation cycles were included in the analysis. Luteal phase stimulation was only started after a negative serum hCG measurement on the day or 1 day before commencement of ovarian stimulation. Ten patients (2.1%) had an undetected natural conception pregnancy at the time of luteal phase stimulation start. Eight of these patients underwent an ovarian stimulation in a GnRH-antagonist protocol and two in a progestin-primed stimulation protocol (PPOS). Recombinant FSH was used as stimulation medication for all patients, the patients with a PPOS protocol received additional recombinant LH. One pregnancy (0.2%) was detected after the oocyte retrieval, the other nine pregnancies were detected either due to persistent high serum progesterone levels or due to an increasing progesterone level after an initial decrease before oocyte retrieval. In the cycles with an undetected natural conception pregnancy, the median number of stimulation days was 8 days (range: 6–11 days) and median serum hCG at detection of pregnancy was 59 IU hCG (range: 14.91–183.1). From 10 patients with a pregnancy, three patients delivered a healthy baby, two patients had ongoing pregnancies at the time of summarizing the data, three patients had biochemical pregnancies (patient age: 30, 39, and 42 years), one patient had an ectopic pregnancy which required a salpingectomy, and one patient (age: 34 years) had an early pregnancy loss.LIMITATIONS, REASONS FOR CAUTIONThe retrospective study design and the small sample size can limit the accuracy of the estimates.WIDER IMPLICATIONS OF THE FINDINGSOverall, there is a small risk of undetected natural conception pregnancies when luteal phase stimulation is undertaken. It appears that there are no adverse effects through either direct effect on the embryo or indirectly through a detrimental effect on the corpus luteum function on the pregnancy in our cohort.STUDY FUNDING/COMPETING INTEREST(S)This study did not receive funding. The authors declare that there is no conflict of interest.TRIAL REGISTRATION NUMBERN/A.

2024-08-01·Reproductive Sciences

Low Dose hCG Support in Modified Natural Frozen Embryo Transfer Cycles

Article

作者: Pabuccu, Emre ; Pabuccu, Recai ; Deniz, Deniz Han ; Valadova, Aytekin

What is the effect of a single low-dose recombinant hCG injection after embryo transfer (ET) in letrozole-induced modified natural frozen embryo transfer cycles (mNC-FET)?. An observational study was conducted in the university-affiliated referral clinic between 2022 and 2024. Women aged 18-42 with at least one vitrified blastocyst obtained from the previous cycle(s) were included. Ovulation induction for endometrial preparation was initiated with oral letrozol (5 mg/day) for five days. Ovulation was triggered using 6500 IU rec hCG sc when the leading follicle > 17 mm, endometrial thickness > 7.5 mm, and serum progesterone (P) < 1.5 ng/ml. All women received 30 mg dydrogesterone/day po for additional five-day luteal support. On the 6th day, ET was performed. Based on a quasi-randomized design, a group of women additionally received a half single bolus of (3250 IU) rec hCG (sc) on the morning of 3rd day of ET (hCG group). Women who did not receive additional hCG were assigned as controls. One hundred fifty-four women were detected to be eligible for the study among 2150 initiated FET cycles during the period. Demographic data of the groups, including mean women's age, BMI, serum AMH, and infertility etiologies, were comparable in terms of variables. Mean serum progesterone values and the number of transferred embryos were also similar. A significantly higher ongoing pregnancy/started cycle was documented in the hCG group than in controls (46.7% vs 33.6% respectively, p = 0.03*). A single low-dose hCG injection after ET may improve the OPRs of women in letrozole mNC-FET cycles.

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Bicetre Hospital (ESPE2022)	N/A	卡尔曼综合征	18	rhLH and rhFSH CSI	(遞鬱憲鹹餘繭襯獵鏇壓) = 膚齋糧鏇廠製夢憲構觸構積積鬱衊繭餘積衊窪 (遞壓夢憲廠衊糧衊網鑰 )	积极	2022-09-15
				recombinant LH	(遞鬱憲鹹餘繭襯獵鏇壓) = 膚簾憲艱網築願觸簾顧構積積鬱衊繭餘積衊窪 (遞壓夢憲廠衊糧衊網鑰 )
NCT01457703 (CTgov)	N/A	肥胖	62	Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI ≥30 kg/m2)	製簾淵膚鹹餘觸積鹹艱(鹹鹹艱顧獵壓齋遞淵夢) = 簾製憲淵壓顧衊壓積獵積遞願餘憲製壓艱夢醖 (夢鏇廠遞築繭積醖觸製, 範衊廠範簾膚廠齋顧簾 ~ 鑰壓蓋鑰願膚廠構顧鹹) 更多	-	2015-03-25
				Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI 18-25 kg/m2)	製簾淵膚鹹餘觸積鹹艱(鹹鹹艱顧獵壓齋遞淵夢) = 觸簾願繭構餘網選簾觸積遞願餘憲製壓艱夢醖 (夢鏇廠遞築繭積醖觸製, 繭窪壓艱簾膚艱積廠鑰 ~ 衊遞簾窪觸簾顧鬱製遞) 更多